MerusMRUS
MRUS
About: Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Employees: 260
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
36% more call options, than puts
Call options by funds: $5.1M | Put options by funds: $3.75M
33% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 54
19% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 31
8% more funds holding in top 10
Funds holding in top 10: 12 [Q3] → 13 (+1) [Q4]
2% more funds holding
Funds holding: 188 [Q3] → 192 (+4) [Q4]
1.6% more ownership
Funds ownership: 101.19% [Q3] → 102.79% (+1.6%) [Q4]
14% less capital invested
Capital invested by funds: $3.45B [Q3] → $2.96B (-$494M) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$70
68%
upside
Avg. target
$87
110%
upside
High target
$109
162%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Wells Fargo Eva Fortea Verdejo 45% 1-year accuracy 5 / 11 met price target | 114%upside $89 | Overweight Maintained | 8 May 2025 |
Needham Ami Fadia 28% 1-year accuracy 44 / 157 met price target | 100%upside $83 | Buy Reiterated | 9 Apr 2025 |
Guggenheim Michael Schmidt 38% 1-year accuracy 17 / 45 met price target | 162%upside $109 | Buy Reiterated | 28 Mar 2025 |
B of A Securities Tazeen Ahmad 26% 1-year accuracy 8 / 31 met price target | 68%upside $70 | Buy Maintained | 10 Mar 2025 |
HC Wainwright & Co. Andrew Fein 29% 1-year accuracy 98 / 337 met price target | 105%upside $85 | Buy Reiterated | 3 Mar 2025 |
Financial journalist opinion
Based on 6 articles about MRUS published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
Merus Announces the Journal Publication of Petosemtamab Mechanism of Action
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Neutral
GlobeNewsWire
1 week ago
Merus to Present at BofA Securities 2025 Health Care Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Negative
Zacks Investment Research
1 week ago
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates
Merus N.V. (MRUS) came out with a quarterly loss of $1.40 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $0.59 per share a year ago.
Neutral
GlobeNewsWire
1 week ago
Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO® Annual Meeting
Negative
Zacks Investment Research
1 week ago
Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to Decline
Merus (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
3 weeks ago
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation
Positive
Seeking Alpha
1 month ago
Merus: Riding The Bispecific Wave In Oncology
Merus stands out in biotech with its innovative Biclonics and Multiclonics platforms, focusing on bispecific and multispecific antibodies, particularly petosemtamab. Strong financials with $724 million cash runway through 2028, allowing strategic R&D investments without immediate capital market pressures. Petosemtamab shows robust clinical data, receiving two FDA Breakthrough Therapy designations, indicating significant potential in treating HNSCC and other cancers.
Neutral
GlobeNewsWire
1 month ago
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025 at 8:45 a.m. ET.
Negative
Zacks Investment Research
2 months ago
Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates
Merus N.V. (MRUS) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $1.09 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update
- Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25
Charts implemented using Lightweight Charts™